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Exome sequencing is an effective strategy for identi-
fying human disease genes. However, this methodol-
ogy is difficult in late-onset diseases where limited324 Neuron 84, 324–331, October 22, 2014 ª2014 Elsevier Inc.availability of DNA from informative family members
prohibits comprehensive segregation analysis. To
overcome this limitation, we performed an exome-
wide rare variant burden analysis of 363 index cases
with familial ALS (FALS). The results revealed an
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Identification of TUBA4A Mutations in ALSexcess of patient variants within TUBA4A, the gene
encoding the Tubulin, Alpha 4A protein. Analysis of
a further 272 FALS cases and 5,510 internal controls
confirmed the overrepresentation as statistically sig-
nificant and replicable. Functional analyses revealed
that TUBA4A mutants destabilize the microtubule
network, diminishing its repolymerization capability.
These results further emphasize the role of cytoskel-
etal defects in ALS and demonstrate the power of
gene-based rare variant analyses in situations where
causal genes cannot be identified through traditional
segregation analysis.
INTRODUCTION
The identification of mutations for human disorders is critical for
our understanding of their pathogenesis. Although numerous
studies have successfully used exome sequencing to identify
novel disease genes, this approach is still limited by the fact
that each individual harbors many rare variants, thus requiring
DNA from multiple affected individuals from an affected family
to be successful. Unfortunately, for many diseases the collection
ofmultiple affected samples from the same family canbedifficult.
This is especially true for familial amyotrophic lateral sclerosis
(FALS), a late-onset, rapidly progressive neurodegenerative
disease. As such, there is a need to develop approaches to use
individual affected cases to identify disease genes. Exome-
wide rare variant analysis has been proposed as a promising
alternative strategy (Panoutsopoulou et al., 2013; Stitziel et al.,
2011). By this approach, the total number of gene variants seen
in cases is compared to that in controls. Threshold minor allele
frequency and possibly functional significance filters are imple-
mented to prevent statistical noise from common or neutral
variants masking true gene associations. Importantly, although
an abundance of variants in cases suggests the presence of
pathogenic mutations, an associated variant set will still likely
include neutral variants in both cases and controls. Since it
does not rely on related samples, we decided to use this
approach to identify novel causative genes for FALS.
RESULTS
We performed exome sequencing on a discovery cohort of
363 index cases (i.e., one affected sample per family) from
six countries (Supplemental Experimental Procedures available
online) devoid of mutations/repeat expansions in known ALS
genes (SOD1, C9orf72, TARDBP, FUS, PFN1, UBQLN2,
OPTN, VCP, and ANG). An average of 3.2 3 109 target bases
was sequenced per sample to an average depth of 90.43.
Control exome data included 4,300 European Americans avail-
able through the NHLBI’s Exome Variant Server (EVS) (Tennes-
sen et al., 2012) and 31 internally sequenced samples. As proof
of principle, we spiked our sample set with nine FALS exomes
with known causative mutations (six in SOD1 and three in VCP).
The analysis was restricted to the 12,487 genes fulfilling all
quality control filters and to variants either predicted to bedamaging by PolyPhen-2 or resulting in a stop gain/loss.
Variants were also only considered if they exhibited minor
allele frequencies less than 0.04%, in keeping with previously
reported ALS mutations (Chio` et al., 2012; Kenna et al.,
2013) (Supplemental Experimental Procedures). The signifi-
cance of disease associations following multiple test correction
(Pcorrected) was calculated using permutation procedures (Kie-
zun et al., 2012). Strong signals of disease association were
observed for SOD1 (6 cases [1.6%] versus 0 controls, p =
5.5 3 108, Pcorrected = 6.2 3 10
4) and VCP (3 cases [0.8%]
versus 0 controls, p = 1.1 3 104, Pcorrected = 0.73) (Figure 1A
and Figure S1). Excluding SOD1, the top hit from our analysis
was TUBA4A, encoding the Tubulin, Alpha 4A protein (4 cases
[1.1%] versus 0 controls, p = 9.1 3 106, Pcorrected = 0.09).
Similar significance for TUBA4A was also obtained when using
alternative bioinformatic tools to identify putatively damaging
variants (SIFT, GERP, MutationTaster, and phyloP). TUBA4A
ranked first or second in all tests (Table S1 and Figure S1),
while no other gene ranked in the top ten hits for all five tests.
Besides TUBA4A, our strategy revealed other strong candidate
genes for FALS (Figure 1A; Table S1), including MATR3,
responsible for distal myopathy 2 and recently identified as
causative for FALS (Johnson et al., 2014). Based on these
results, we further investigated TUBA4A as a candidate gene
associated with FALS.
Exome sequencing revealed a total of five nonsynonymous
TUBA4A changes, all localized in exon 4 and confirmed by
Sanger sequencing (Table S2). None of them were observed in
the 4,300 EVS controls and all occurred at highly conserved
positions (Figure 1B). The mutations included two missense
changes in the same residue (R320C/H) and a nonsense muta-
tion (W407X) removing the last 41 amino acids. This C-terminal
region contacts the b-tubulin subunit as well as the motor
domain of kinesins and other microtubule-associated proteins
(Howes et al., 2014; Liu et al., 2012) (Figure 1C). Additional
missense changes included R215C and A383T mutations. Poly-
Phen-2 predicted four of the five mutations to be deleterious
(Table S2). In contrast, only three nonsynonymous changes
were observed in the 4,300 EVS controls (V68A, I276V, and
V375M), all predicted to be benign. No relatives of the affected
patients were available to test segregation.
To further evaluate TUBA4A as a causative ALS gene, we
sequenced an independent replication cohort comprising a
further 272 index FALS cases and 5,510 internal European
American controls for rare damaging exon 4 variants. Reimple-
mentation of the variant filtering strategies employed during
the discovery analysis and subsequent testing using Fisher’s
exact method revealed a significant excess of mutation carriers
among patients (2 cases [0.65%] versus 2 controls [0.04%], p =
1.5 3 102). A combined analysis of the discovery and replica-
tion cohorts resulted in a statistically significant overabundance
of rare variants after multiple test correction (OR = 36 [95%
CI: 10–210], p = 4.3 3 107, Pcorrected = 4.2 3 10
3). Of the
two mutations observed in the replication cohort, a T145P
variant segregated with disease within the family, while a
K430N variant was not detected in an affected first cousin of
the sequenced proband (Figure S1C), suggesting that this is
either a neutral polymorphism, as is often observed in rareNeuron 84, 324–331, October 22, 2014 ª2014 Elsevier Inc. 325
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Figure 1. Rare Variant Analysis Identifies TUBA4A Mutations in FALS
(A) Manhattan plot displaying permutation-based corrected p values generated by a rare variant analysis of FALS. The dotted line represents a Pcorrected = 0.05.
The points in yellow, red, and black for TUBA4A denote the p value for the discovery, replication, and joint analyses, respectively. (B) The evolutionary con-
servation of TUBA4A mutations is displayed. Mutated residues are shown in red. (C) The interactions of bovine TUBA1B and TUBB2B with the rat kinesin KIF5B
(Protein Data Bank accession number 4ATX) are shown using the PyMOL Molecular Graphics System (v.1.5.0.5). All relevant residues are identical between
bovine TUBA1B and human TUBA4A. Light blue, a-tubulin; green, b-tubulin; orange, kinesin; red, mutant or deleted residues identified in this study; spheres,
residues involved in interprotein interactions. As shown, the C-terminal region interacts with both b-tubulin and the kinesin motor domain.
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Identification of TUBA4A Mutations in ALSvariant analyses, or the two affected family members are phe-
nocopies. Variants identified in controls included E386K and
G365E substitutions but none of the variants detected in
FALS patients from either the discovery or replication cohorts.
Sequencing of the entire coding region in 1,355 sporadic ALS
(SALS) cases also identified a G43V mutation in a single sample
(Table S2). This variant was predicted to be benign by Poly-
Phen-2 and detected within 1 control from the internal replica-
tion panel. No TUBA4A mutations were identified in 131 ALS
samples (89 FALS and 42 SALS) with known mutations/repeat
expansions.
All patients carrying TUBA4A mutations had spinal-onset,
classical ALS, with upper and lower motor neuron signs. Two
cases also developed a cognitive decline of frontal type, consis-
tent with a diagnosis of frontotemporal dementia (FTD) and
another had a first-degree relative with FTD (Figure S1 and Table
S3). Screening of 1,053 samples analyzed by the 1000 Genome
project and 2,200 African Americans from the EVS revealed the
A383T mutation within a single individual of African ancestry.
Therefore, with the exception of A383T and G43V, the set of
observed patient variants were not detected within a total of
13,023 control samples (Table S4).
TUBA4A Mutants Display Altered Incorporation
into Microtubules
Since several causative ALS proteins form insoluble inclusions
in postmortem brain tissues and in cell culture, we investigated326 Neuron 84, 324–331, October 22, 2014 ª2014 Elsevier Inc.the ability of TUBA4A mutants to aggregate by expressing
hemagglutinin (HA)-tagged TUBA4A constructs in primary mo-
tor neurons (PMNs) and HEK293 cells. Interestingly, the W407X
mutant did not incorporate into the microtubule network
and formed small ubiquitinated cytoplasmic inclusions in
40% of transfected PMNs and 85% of transfected HEK293
cells (Figures 2A and 2B; Figure S2). Immunohistochemistry
of brain and spinal cord tissue from SALS cases (without muta-
tions) yielded a clear staining of the perikarya and neuropil
region in both the spinal cord and motor cortex; however, no
TUBA4A aggregates were identified (Figure S2). No coaggre-
gation was observed in cells coexpressing an aggregation-
prone TDP-43 C-terminal fragment and wild-type TUBA4A (Fig-
ure S2). While the other TUBA4A mutants formed cytoplasmic
inclusions in 10%–30% of transfected HEK293 cells (data not
shown), no aggregation was observed in PMNs. However, sub-
tle alterations in their cytoplasmic distribution were observed,
such as a more diffuse staining compared to the wild-type pro-
tein, which was mainly incorporated into the microtubule
network (Figure 2A). We thus investigated the ability of mutant
TUBA4A to efficiently form microtubules using a cell-free
system to quantify its incorporation into a-/b-tubulin dimers
(Cleveland et al., 1978; Jaglin et al., 2009; Tian et al., 2010).
Each mutant was subjected to in vitro translation in rabbit
reticulocyte lysate that contains all components needed to
form tubulin dimers. The products were then analyzed by non-
denaturing gel electrophoresis to measure incorporation of the
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Figure 2. Mutant TUBA4A Alters Microtubule Polymerization
(A) PMNs transfected with HA-tagged TUBA4A constructs. (B) HEK293 cells expressing wild-type or mutant HA-TUBA4A were immunostained for ubiquitin.
Ubiquitin-positive aggregates were visible only in the HA-TUBA4AW407X-transfected cells. (C) Nondenaturing (top) and SDS-gel electrophoresis (bottom) of
HA-TUBA4A constructs after in vitro translation. (D) The intensity of the bands representing the a-/b-tubulin dimerswas quantified. Bars representmean and SEM
(one-way ANOVA andDunnett’s post hoc test, n = 6, *p < 0.05, ***p < 0.001). (E) Representative images of primary astroglial cells transfectedwith the HA-TUBA4A
constructs. (F) The ratio between HA-TUBA4A protein distributions in filaments versus its overall levels was measured and distributed into four categories from
mainly filamentous to mainly diffuse. The frequency of each phenotype was compared between the wild-type and mutant proteins (Kolmogorov-Smirnov test;
n = 75–90 cells per condition from 3 experiments, **p < 0.01, ***p < 0.001). From left to right, bars represent the relative frequencies of the normal, mild, moderate,
and severe phenotypes. Red, HA; green, ubiquitin; blue, DAPI. White boxes indicate the regions enlarged in the insets. Scale bars, 10 mm.
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Identification of TUBA4A Mutations in ALStranslated recombinant protein into tubulin dimers. Interestingly,
TUBA4AW407X yieldednodiscernible dimers,while theA383Tand
both R320mutants displayed significantly lower levels of assem-
bly relative to thewild-type protein (Figures 2Cand 2D). The other
mutants did not differ from the control, save for a small but repro-
ducible migration difference for TUBA4AR215C. In parallel, we
tested the incorporation of mutant TUBA4A into microtubules in
cultured cells. We chose primary astroglial cells, as they have a
large cytoplasm and a relatively long cell cycle that result in an
extensive and stable microtubule network. We performed an un-
biased analysis of the cytoskeletal incorporation of HA-tagged
TUBA4A constructs. The ratio between the fluorescence inten-
sities of the filamentous versus overall staining, ranging from 1
to 0, was used to categorize each cell as normal (1–0.75), mild
(0.75–0.5), moderate (0.5–0.25), or severe (0.25–0) (Figures 2E
and 2F and Figure S3). Thewild-typeHA-tagged TUBA4Aproteinyielded nearly 70% of cells displaying a high level of microtubule
incorporation. In contrast, several mutants displayed an altered
incorporation into microtubules. In particular, the W407X yielded
themost dramatic effect with an absence of tagged protein in the
microtubule network and the presence ofmultiple aggregate-like
inclusions. The R320C/H, A383T, and R215C mutants all dis-
played a significantly different distribution relative to the wild-
type, but no differences were detected for the G43V protein.
TUBA4A Mutants Disrupt Microtubule Dynamics and
Stability through a Dominant-Negative Mechanism
We next determined whether TUBA4Amutants affected microtu-
bule dynamics by testing the ability of transfected COS7 cells to
recover after transient microtubule depolymerization (Figure 3)
(Gilissen et al., 2011; Tian et al., 2008, 2010). For this assay, the
wild-type, R320C, andW407X proteins were compared, as theseNeuron 84, 324–331, October 22, 2014 ª2014 Elsevier Inc. 327
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Figure 3. Mutant TUBA4A Alters Microtubule Dynamics
(A and C) Representative images of nocodazole-treated COS7 cells expressing wild-type and mutant TUBA4A (A, TUBA4AR320C; C, TUBA4AW407X). Cells were
allowed to recover in nocodazole-free medium for 2.5, 5, 10, or 15 min prior to fixation. Red, HA; green, TUBA4A; blue, DAPI. White boxes indicate the regions
enlarged in the insets. Scale bars, 10 mm. (B and D) The percentage of cells containing microtubules positive for the HA-tagged or the endogenous TUBA4A
protein was quantified from more than 100 cells per condition from 3 independent experiments and compared between wild-type and mutant TUBA4A
(B, TUBA4AR320C; D, TUBA4AW407X). Points represent mean and SEM (one-way ANOVA and Dunnett’s post hoc test; *p < 0.05, **p < 0.01, ***p < 0.001).
Neuron
Identification of TUBA4A Mutations in ALSmutants displayed an intermediate and severe phenotype,
respectively, in the previous experiments. While 80% of cells
transfected with TUBA4AWT formed centrosomes positive for
the HA-tagged TUBA4A protein within 5 min of nocodazole
removal, only 20% of TUBA4AR320C-transfected cells formed
new microtubules containing the mutant protein at 15 min. The
expression of mutant TUBA4A also impaired the ability of
the endogenous protein to form microtubules, as only 50%
of the cells contained TUBA4A-positive microtubules after
15 min, compared to 90% in wild-type-transfected cells
(Figures 3A and 3B). Similar results were also observed in cells
containing TUBA4AW407X-positive aggregates. On the contrary,
cells expressing the TUBA4AW407X mutant without the presence
of aggregates did not display any defect in the rate ofmicrotubule
repolymerization (Figures 3C and 3D). These results suggest328 Neuron 84, 324–331, October 22, 2014 ª2014 Elsevier Inc.that mutant TUBA4A by incorporating into the microtubules may
disrupt their dynamics through a dominant-negative mechanism.
To pursue this hypothesis, we investigated whether TUBA4A
mutants would influence the overall stability of the microtubule
network. PMNs expressing wild-type and mutant TUBA4A
constructs were permeabilized with 0.1% Triton X-100 to
extract soluble proteins before fixation and immunostained
for HA-TUBA4A and b-tubulin. Under these conditions, the
cytoskeleton was largely preserved in wild-type-transfected
neurons, whereas each of the missense mutants resulted in
decreased HA-TUBA4A and b-tubulin immunofluorescence
(Figures 4A–4C). Furthermore, the levels of a-tubulin acetyla-
tion, which have been shown to correlate with increased micro-
tubule stability (Matsuyama et al., 2002; Piperno et al., 1987),
were significantly reduced in mutant TUBA4A-expressing
TU
B
A
4A
W
T
TU
B
A
4A
G
43
V
TU
B
A
4A
R
21
5C
TU
B
A
4A
R
32
0C
TU
B
A
4A
R
32
0H
TU
B
A
4A
A
38
3T
HA β-Tubulin Merge
β-Tubulin Merge
β-Tubulin Merge
β-Tubulin Merge
β-Tubulin Merge
β-Tubulin Merge
HA
WT
G4
3V
R2
15
C
R3
20
C
R3
20
H
A3
83
T
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
N
or
m
. F
lu
or
es
ce
nc
e 
In
te
ns
ity
* *
* *
***
HA-TUBA4A
WT
G4
3V
R2
15
C
R3
20
C
R3
20
H
A3
83
T
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
N
or
m
. F
lu
or
es
ce
nc
e 
In
te
ns
ity
β-Tubulin
***
*** **
**
**
* *** **
N
or
m
. F
lu
or
es
ce
nc
e 
In
te
ns
ity
WT
G4
3V
R2
15
C
R3
20
C
R3
20
H
A3
83
T
HA
HA
HA
HA
A
B C
D
E
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4Tu
ba
4A
W
T
Tu
ba
4A
G4
3V
Tu
ba
4A
R2
15
C
Tu
ba
4A
R3
20
C
Tu
ba
4A
R3
20
H
Tu
ba
4A
A3
83
T
HA Ac-tubulin
HA Ac-tubulinHA Ac-tubulin
HA Ac-tubulinHA Ac-tubulin
HA Ac-tubulin
Figure 4. Mutant TUBA4A Destabilizes the Microtubule Network
(A) PMNs transfected with wild-type or mutant TUBA4A constructs were permeabilzed with 0.1% Triton X-100 for 5 min prior to fixation. (B and C) The fluo-
rescence intensity of (B) HA-TUBA4A and (C) b-tubulin was quantified and compared. Bars represent mean and SEM (Kruskal-Wallis test, n = 23–34 cells per
condition from 3 independent experiments, *p < 0.05, **p < 0.01, ***p < 0.001). (D and E) Acetylated tubulin (green) levels were measured in PMNs expressing
TUBA4Amutants (red). Representative images are shown (D). Bars represent mean and SEM (E, one-way ANOVA andDunnett’s post hoc test, n = 30–45 cells per
condition from 3 independent experiments, *p < 0.05, **p < 0.01). Scale bars, 10 mm.
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Identification of TUBA4A Mutations in ALSPMNs (Figures 4D and 4E). Of note, the G43V mutation, which
is uniquely localized to the protein N terminus, did not impair
tubulin acetylation, suggesting that defective binding of the
acetyl-transferase aTAT1 to a-tubulin C-terminal tail (Howes
et al., 2014; Panoutsopoulou et al., 2013; Stitziel et al., 2011),
where TUBA4A mutations are clustered, may be responsible
for this effect. Together, these results further suggest thatmissense mutants of TUBA4A weaken the microtubule network
by a dominant-negative mechanism.
DISCUSSION
To summarize, we have used an unbiased case-control exome-
sequencing study to identify a statistically significant andNeuron 84, 324–331, October 22, 2014 ª2014 Elsevier Inc. 329
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Identification of TUBA4A Mutations in ALSreplicable excess of rare damaging TUBA4A variants in FALS.
Disease-associated variants affect conserved residues and in
most cases are absent in over 13,000 controls. The positive
identification of samples with mutations in the SOD1 and VCP
genes, as well as in the newly discovered ALS gene MATR3
within the initial cohort, further proves the validity of our
approach. Though our burden approach demonstrated the
importance of a specific class of TUBA4A variants, a limitation
is that it is not informative as to the effects of individual
variants. Thus, not all reported patient mutations may be patho-
genically relevant or act with equal penetrance. An example
of this is the K430N alteration not segregating in an affected first
cousin. However, our results from biological characterization
provided strong evidence to support a deleterious effect of
most variants. Specifically, FALS-associated variants (1) ineffi-
ciently form a-/b- tubulin dimers in vitro,(2) display decreased
incorporation into microtubules in cultured cells, and (3) inhibit
microtubule network assembly and reduce structural stability.
Based on these data, TUBA4A mutants appear to disrupt micro-
tubule dynamics and stability through a dominant-negative
mechanism. Interestingly, the truncation mutant TUBA4AW407X
is deficient in forming dimers or incorporating into the microtu-
bule network, suggesting that it may have a decreased ability
to act as a dominant negative. This is illustrated by our observa-
tion that in cells expressing the W407X mutant without aggre-
gates, there is no obvious defect in the rate of microtubule repo-
lymerization. However, since TUBA4AW407X shows aggregation
propensities analogous to other ALS-associated mutant pro-
teins, its deleterious effect may be through a different mecha-
nism, such as trapping tubulin-binding proteins into aggregates
or by overburdening the ubiquitin proteasome system.
Mutations in at least seven other tubulin family members
(TUBA1A [Keays et al., 2007; Kumar et al., 2010; Poirier et al.,
2007], TUBA8 [Abdollahi et al., 2009], TUBB2B [Jaglin et al.,
2009], TUBB3 [Poirier et al., 2010; Tischfield et al., 2010], TUBB5
[Breuss et al., 2012], TUBB4A [Hersheson et al., 2013; Tian
et al., 2008], andTUBG1 [Poirier et al., 2013]) havebeendescribed
to cause several neurodevelopmental and neurodegenerative dis-
orders. Moreover, the progressive motor neuronopathy (pmn)
mutant mouse, a commonly usedmodel for humanmotor neuron
disease, bears a mutation in the Tubulin-specific Chaperone E
(TBCE) gene (Bo¨mmel et al., 2002; Martin et al., 2002). Most
mutant tubulin proteins show similar functional defects compared
to TUBA4A mutants, such as impaired dimerization and microtu-
bule incorporation and yet cause very different phenotypes. Inter-
estingly, results from the BrainSpan Atlas and in developing
mouse brain tissue show that most a- and b-tubulin subunits
responsible for developmental defects are highly expressed dur-
ing brain development and decrease with age, whereas TUBA4A
levels increase dramatically (>50-fold) with age (Figure S4).
Furthermore, similar to TUBA4A, expression of TUBB4A also in-
creases over time and mutations in this gene are responsible for
a disease with an onset age of 15–37 years (torsion dystonia
type 4) (Hersheson et al., 2013). These observations may partially
explain the difference between the neurodevelopmental and late-
onset symptoms associated to the different tubulin mutations.
TUBA4A is ubiquitously expressed in human tissues with its
highest expression in brain (Rustici et al., 2013). Although a330 Neuron 84, 324–331, October 22, 2014 ª2014 Elsevier Inc.downregulation of a-tubulin subunit genes has been reported
inmotor neurons of SALS patients (Jiang et al., 2005), no specific
role has been described for TUBA4A in motor neurons so far.
TUBA4A joins other ALS-associated genes encoding for cyto-
skeletal proteins, such as PFN1 (Wu et al., 2012), DCTN1 (Puls
et al., 2003), PRPH (Gros-Louis et al., 2004), and NEFH (Al-Cha-
labi et al., 1999), thus strengthening the hypothesis that alter-
ations affecting the cytoskeleton architecture and dynamics
have a major role in ALS pathogenesis.
EXPERIMENTAL PROCEDURES
Exome Sequencing and Rare Variant Analysis
Ethical approval for this study was received by the IRBs of the participating
institutions. Exome sequencing reads were aligned to a human reference
(hg19) using Burrows-Wheeler Aligner and processed using the Genome Anal-
ysis ToolKit. Rare variant analyses were performed by logistic regression of
case-control status with respect to the aggregated count of minor alleles in
a given gene window. For each p value from the observed data set analysis,
Pcorrected was calculated as the proportion of permuted data sets where an
association of equal or greater significance was observed across any gene.
Motor Neuron Culture and Transfection
PMNs were cultured from embryonic day 12.5 embryos and transfected at
2 days in vitro, as previously described (Fallini et al., 2010).
Quantification of Microtubule Incorporation
Using ImageJ, a region of interest (ROI) was selected for each HA-TUBA4A-
positive cell and the signal was thresholded to remove background noise. A
circularity filter (circularity index R 0.2) was then applied to remove gran-
ular staining. The ratio between the fluorescence intensities of the filtered cyto-
skeleton versus the thresholded ROI yielded an incorporation index ranging
from 0 (no incorporation) to 1 (complete microtubule incorporation).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.neuron.2014.09.027.
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